Butantan Vaccine reaches 100% effectiveness for moderate and severe cases.

The Government of São Paulo and the Butantan Institute confirmed on this Thursday (7) that the vaccine against coronavirus developed in partnership with biopharmaceutical Sinovac Life Science reached an efficacy rate of 100% for severe and moderate cases. The clinical study which was carried out in Brazil was attended by 12,400 volunteer health professionals in 16 research centers.

“Today is a very important day for Brazil, Brazilians, health and life. Instituto Butantan’s vaccine is 78% to 100% effective against COVID-19, according to studies in Brazil,” said Governor João Doria. “As Governor of São Paulo, I want to thank the more than 12 thousand volunteers who agreed to participate in this research coordinated by Butantan and centers of excellence in eight Brazilian states. Also thank the researchers, doctors and scientists who helped and contributed to find this great result. Our recognition and our gratitude. ”

Among those immunized during clinical tests and who contracted the virus, none had a severe or moderate case of the disease or needed hospitalization. In other words, whoever takes the Butantan vaccine will have their health protected and minimal chances of worsening COVID-19.

The efficacy rate was 78% for those infected with mild cases or who needed outpatient care. This means that for every hundred volunteers who contracted the virus, only 22 had only mild symptoms, but without the need for hospitalization.

With the rates reached in the survey, Butantan started this Thursday to request the emergency registration of the vaccine with Anvisa (National Health Surveillance Agency), so that the immunization of Brazilians against COVID-19 can be started quickly.

“The vaccine has shown 100% effectiveness against severe and moderate cases. There was no serious case of COVID-19 among volunteers immunized with the Butantan vaccine,” explained the institution’s director, Dimas Tadeu Covas.

By Niyi Fote/Thenews2